507186196 03/18/2022

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7233043

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT		

CONVEYING PARTY DATA

Name	Execution Date
TONI WEINSCHENK	02/05/2016
STEFFEN WALTER	01/29/2016
JENS FRITSCHE	02/08/2016
COLETTE SONG	02/08/2016
HARPREET SINGH	02/01/2016

RECEIVING PARTY DATA

Name:	IMMATICS BIOTECHNOLOGIES GMBH
Street Address:	PAUL-EHRLICH-STR. 15
City:	TUEBINGEN
State/Country:	GERMANY
Postal Code:	72076

PROPERTY NUMBERS Total: 2

Property Type	Number
Application Number:	17698526
Application Number:	17698531

CORRESPONDENCE DATA

Fax Number: (301)476-4851

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: docketing@mmviplaw.com, eanthony@mmviplaw.com,

awatson@mmviplaw.com

Correspondent Name: MCBEE, MOORE & VANIK IP, LLC
Address Line 1: 510 SOUTH MARKET STREET
Address Line 4: FREDERICK, MARYLAND 21701

ATTORNEY DOCKET NUMBER:	TORNEY DOCKET NUMBER: 2912919-032019; -032020		
NAME OF SUBMITTER:	ERICA ANTHONY		
SIGNATURE:	/Erica Anthony/		
DATE SIGNED:	03/18/2022		
	This document serves as an Oath/Declaration (37 CFR 1.63).		

PATENT REEL: 059313 FRAME: 0205

Total Attachments: 4

source=2912919-032019_Declaration-Assignment#page1.tif source=2912919-032019_Declaration-Assignment#page2.tif

 $source = 2912919 - 032019 _ Declaration - Assignment \# page 3.t if$

source=2912919-032019_Declaration-Assignment#page4.tif

PATENT REEL: 059313 FRAME: 0206

Docket No.: 2912919-032001

ASSIGNMENT WITH DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)

ASSIGNMENT

Whereas, I/We, the undersigned inventor(s) hereinafter called assignor(s), have invented certain improvements described in the application identified below; and

Whereas, IMMATICS BIOTECHNOLOGIES GMBH of Tuebingen, Germany, (assignee), who business address is Paul-Ehrlich-Strasse 15, 72076, Germany, desires to acquire the entire right, title, and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named assignee, its successors, legal representatives, and assigns, my/our entire right, title and interest, if any, in the invention and the application for the United States of America, including all direct and indirect divisions, continuations, and continuations-in-part thereof, and all original, extended, reissued, reviewed, and reexamined Letters Patent of the United States, and all countries foreign thereto, that may be granted thereon, including rights of priority under the International Convention of Paris (1883) as amended, including the right to claim priority under 35 U.S.C. §119, and I/we request the Director of the U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and I/we hereby agree that the assignee may apply for foreign Letters Patent on the invention and I/we will without further consideration, communicate all facts know to me/us and execute without further consideration all papers deemed necessary by the assignee in connection with the United States and foreign applications when called upon to do so by the assignee, its successors, legal representatives, or assigns. I/We further represent and warrant that I/We have the full right to convey the interest assigned by this assignment, and that I/We have not granted any rights inconsistent with the rights granted herein. I/We further acknowledge an obligation of assignment of this invention to assignee at the time the invention was made.

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)

DECLARATION

As a below named inventor, I hereby declare that this assignment with declaration is directed to:				
	The attached application,	OR		United States Application 14908078 or PCT International Application filed on January 27, 2016 (Confirmation No. 2708).

PRE-AIA

My mailing address and citizenship are as stated below next to my name. I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention titled:

Novel immunotherapy against several tumors, such as lung cancer, including NSCLC

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

POST-AIA

The above identified application was made or was authorized to be made by me.

I believe I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this assignment with declaration is punishable under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

Authorization To Permit Access To Application by Participating Office

☑ If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and any other intellectual property offices in which a foreign application claiming priority to the above-identified application is filed access to the above-identified patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant does not wish the EPO, JPO, KIPO, or other intellectual property office in which a foreign application claiming priority to the above-identified application is filed to have access to the application.

In accordance with 37 CFR 1.14(b)(3), access will be provided to a copy of the application-as-filed with respect to: 1) the above-identified patent application-as-filed, 2) any foreign application to which the above-identified application claims priority under 35 USC 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of 37 CFR 1.55 has been filed in the above-identified patent application, and 3) any U.S. application-as-filed from which benefit is sought in the above-identified patent ambiguition.

In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing the Authorization to Permit Access to Application by Participating Office.

NAME OF SOLE OR FIRST INVENTOR:	
Given Name	
(first and middle [if any]) Toni	Family Name or Surname WEINSCHENK
Inventor's signature	Date 5 Feb 2016
Mailing Address: Im Morgenrain 15, 73773 Aichwald, DE	Citizenship DE
NAME OF SECOND INVENTOR:	
Given Name (first and middle [if any]) Steffen	Family Name or Surname WALTER
Inventor's signature	Date
Mailing Address: 2901 Wroxton Road, Houston 77005, USA	Citizenship DE
NAME OF THIRD INVENTOR:	
Given Name (first and middle [if any]) Jens	Family Name or Surname FRITSCHE
Inventor's signature	Date 8-Feb - 2016
Mailing Address: Laerchenweg 11, 72144, Dusslingen, DE	Citizenship DE
NAME OF FOURTH INVENTOR:	
Given Name (first and middle [if any]) Colette	SONG
Inventor's signature	Date 08.02.2016
Mailing Address: Willi-Baumeister-Weg 21, 73760, Ostfildern, DE	Citizenship DE
NAME OF FIFTH INVENTOR:	
Given Name (first and middle [if any]) Harpreet / A	SINGH
Inventor's signature	Date 1F40J04
Mailing Address: Possartstrasse 16, 81679 Muenchen, DE	Cîtizenshin DE

Docket No.: 2912919-032001

ASSIGNMENT WITH DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)

ASSIGNMENT

Whereas, I/We, the undersigned inventor(s) hereinafter called assignor(s), have invented certain improvements described in the application identified below; and

Whereas, IMMATICS BIOTECHNOLOGIES GMBH of Tuebingen, Germany, (assignee), who business address is Paul-Ehrlich-Strasse 15, 72076, Germany, desires to acquire the entire right, title, and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named assignee, its successors, legal representatives, and assigns, my/our entire right, title and interest, if any, in the invention and the application for the United States of America, including all direct and indirect divisions, continuations, and continuations-in-part thereof, and all original, extended, reissued, reviewed, and reexamined Letters Patent of the United States, and all countries foreign thereto, that may be granted thereon, including rights of priority under the International Convention of Paris (1883) as amended, including the right to claim priority under 35 U.S.C. §119, and I/we request the Director of the U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and I/we hereby agree that the assignee may apply for foreign Letters Patent on the invention and I/we will without further consideration, communicate all facts know to me/us and execute without further consideration all papers deemed necessary by the assignee in connection with the United States and foreign applications when called upon to do so by the assignee, its successors, legal representatives, or assigns. I/We further represent and warrant that I/We have the full right to convey the interest assigned by this assignment, and that I/We have not granted any rights inconsistent with the rights granted herein. I/We further acknowledge an obligation of assignment of this invention to assignee at the time the invention was made.

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)

DECLARATION

As a below named inventor, I hereby declare that this assignment with declaration is directed to:				
	The attached application,	OR	\boxtimes	United States Application 14908078 or PCT International Application
	• • • • • • • • • • • • • • • • • • • •		Number	filed on January 27, 2016 (Confirmation No. 2708).

PRE-AIA

My mailing address and citizenship are as stated below next to my name. I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention titled:

Novel immunotherapy against several tumors, such as lung cancer, including NSCLC

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

POST-AIA

The above identified application was made or was authorized to be made by me.

I believe I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this assignment with declaration is punishable under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

Authorization To Permit Access To Application by Participating Office

☑ If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and any other intellectual property offices in which a foreign application claiming priority to the above-identified application is filed access to the above-identified patent application. See 37 CFR 1.14(e) and (h). This box should not be checked if the applicant does not wish the EPO, JPO, KIPO, or other intellectual property office in which a foreign application claiming priority to the above-identified application is filed to have access to the application.

PATENT REEL: 059313 FRAME: 0209 In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the application-as-filed with respect to: 1) the above-identified patent application-as-filed, 2) any foreign application to which the above-identified application claims priority under 35 USC 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of 37 CFR 1.55 has been filed in the above-identified patent application, and 3) any U.S. application-as-filed from which benefit is sought in the above-identified patent application.

In accordance with 37 CFR 1.14(e), access may be provided to information concerning the date of filing the Authorization to Permit Access to Application by Participating Office.

NAME OF SOLE OR FIRST INVENTOR:					
Given Name					
(first and middle [if any]) Toni	Family Name or Surname	WEINSCHENK			
Inventor's signature	Date				
Mailing Address: Im Morgenrain 15, 73773 Aichwald, DE	Citiz	enship DE			
NAME OF SECOND INVENTOR:					
Given Name					
(first and middle [if any]) Steffen	Family Name or Surname	WALTER			
Inventor's signature	Date	1/29/2016			
Mailing Address: 2901 Wroxton Road, Houston 77005, USA	Citiz	enship DE			
NAME OF THIRD INVENTOR:	, Citiz				
Given Name (first and middle [if any]) Jens	Family Name or Surname	FRITSCHE			
(mst and middle [if any]) Jens	Tanny Name of Sumame	TRESCIE			
Inventor's signature	Date				
Mailing Address: Laerchenweg 11, 72144, Dusslingen, DE	Citiz	enship DE			
NAME OF FOURTH INVENTOR:	y				
Given Name					
(first and middle [if any]) Colette		SONG			
Inventor's signature	Date				
Mailing Address: Willi-Baumeister-Weg 21, 73760, Ostfildern, DE	Citiz	enship DE			
NAME OF FIFTH INVENTOR:					
Given Name		CINICII			
(first and middle [if any]) Harpreet		SINGH			
To contact a denotion	Data				
Inventor's signature	Date				
Mailing Address: Possartstrasse 16, 81679 Muenchen, DE	Citiz	enship DE			
Maning Address. Possarstrasse to, 01079 Minehellell, DE	Citiz	champ DE			

PATENT REEL: 059313 FRAME: 0210

RECORDED: 03/18/2022